Table 2.

Quantitative analyses

	[99mTc]Tc-tilmanocept	[99mTc]Tc-nanocolloid	p value
Radioactivity remaining in injection site	29.9%; SD ± 7.6 (range 17.10–43.95)	60.9%; SD ± 16.1 (range 30.26–89.58)	< 0.001
Uptake in SLNs	1.95%; IQR ± 2.6 (range 0.21–6.80)	3.16%; IQR ± 3.9 (range 0.04–11.90)	0.010
SLN to injection site ratio	0.066; IQR ± 0.1 (range 0.001–0.20)	0.054; IQR ± 0.07 (range 0.001–0.22)	0.232
Number of SLNs	3.0; IQR ± 2 (range 0–4)	2.5; IQR ± 1 (range 1–5)	0.297
Number of higher echelon nodes	2.0; IQR ± 2 (range 0–5)	2.5; IQR ± 3 (range 0–6)	0.083
Uptake in higher echelon nodes	0.57%: IQR ± 1.64 (range 0.001–7.15)	0.86%: IQR ± 2.17 (range 0.001–6.95)	0.052
Background activity	2.23%; IQR ± 2.01 (range 0.93–5.76)	0.41%; IQR ± 0.96 (range 0.01–1.55)	< 0.001
Pain score (NPRS)	3.0; IQR ± 3 (range 0–8)	2.0; IQR ± 4 (range 0–8)	0.041

SD, standard deviation; IQR, interquartile range; SLN, sentinel lymph node